IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Enhancement of Proliferation and Antigen Presentation of Human B Cells in Vitro by K562 Cells Expressing CD40L

CD40L 발현 K562 세포주를 이용한 시험관내 B 세포 증식과 항원제공능 증가

  • Park, Jung-Yong (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Sung-Hee (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Kim, Eun-Kyung (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Yun, Sun-Ok (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Sohn, Hyun-Jung (Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea) ;
  • Kim, Tai-Gyu (Department of Microbiology, College of Medicine, The Catholic University of Korea)
  • 박정용 (가톨릭대학교 의과대학 미생물학교실) ;
  • 윤성희 (가톨릭대학교 의과대학 미생물학교실) ;
  • 김은경 (가톨릭대학교 의과대학 미생물학교실) ;
  • 윤선옥 (가톨릭대학교 의과대학 미생물학교실) ;
  • 손현정 (가톨릭대학교 의과대학 가톨릭조혈모세포은행) ;
  • 김태규 (가톨릭대학교 의과대학 미생물학교실)
  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: CD40-activated B (CD40-B) cells might be an attractive source of autologous antigen-presenting cells (APCs) for immunotherapy due to the convenience to obtain from peripheral blood and expand in vitro. Moreover, CD40-B cells were found to be comparable with DCs in their capacity to raise antigen-specific CD8+ T cells. Here, we have established K562 cells expressing CD40L to expand CD40-activated B cells used for APCs. Methods: After activation of B cell by K562/CD40L, CD40-B cells were examined by counting B cell numbers. Surface expression of CD54, CD80, CD86 and HLA class II was measured by flow cytometry. The CD40-B cells were tested for its function as APC by mixed lymphocyte reactions (MLR) and by induction of T cell responses specific for pp65 peptide in vitro. Results: The expansion of B cells by K562/CD40L increased about 6-folds compared with anti-CD40 or K562. Furthermore, the expression of CD54, CD80, CD86 and HLA class II was up-regulated by K562/CD40L. B cells by K562/CD40L showed comparable antigen presentation activity with mature DCs as shown in MLR, INF-${\gamma}$ ELISPOT assay. Conclusion: These results suggest that K562/CD40L could be used to generate activated B cells as potent APCs which could be useful for cellular vaccination and adoptive immunotherapy.

Keywords

References

  1. Steinman RM, Witmer-Pack M, Inaba K: Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 329;1-9, 1998
  2. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL: Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99;3319-3325, 2002 https://doi.org/10.1182/blood.V99.9.3319
  3. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190;1669-1678, 1999 https://doi.org/10.1084/jem.190.11.1669
  4. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109;409-417, 2002 https://doi.org/10.1172/JCI0214364
  5. Maier T, Tun-Kyi A, Tassis A, Jungius KP, Burg G, Dummer R, Nestle FO: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102;2338-2344, 2003 https://doi.org/10.1182/blood-2002-08-2455
  6. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6;332-336, 2000 https://doi.org/10.1038/73193
  7. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM: CD40- activated human B cells: an alternative source of highly efficient antigen-presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100;2757-2765, 1997 https://doi.org/10.1172/JCI119822
  8. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto K, Harada M, Takahashi T, Akatsuka Y: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 169;2164-2171, 2002 https://doi.org/10.4049/jimmunol.169.4.2164
  9. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16;111-135, 1998 https://doi.org/10.1146/annurev.immunol.16.1.111
  10. Ivanov R, Aarts T, Hagenbeek A, Hol S, Ebeling S: B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. Cytotherapy 7;62-73, 2005 https://doi.org/10.1080/14653240510018055
  11. Yoon SH, Cho HI, Kim TG: Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro. Exp Mol Med 37;567-574, 2005 https://doi.org/10.1038/emm.2005.70
  12. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH: RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103;2046-2054, 2004 https://doi.org/10.1182/blood-2003-07-2379
  13. Okamura T, Uluhan S, Rooney CM: Antigen-presenting ca pabilities of retrovirus-transduced T cell blasts. Blood 102;285a, 2003
  14. Liu YN, Fuad S, Gehrz RC: Epstein-Barr virus-transformed lymphoblastoid cell lines as antigen-presenting cells and 'augmenting' cells for human CMV-specific Th clones. Cell Immunol 108;64-75, 1987 https://doi.org/10.1016/0008-8749(87)90193-6
  15. Ascher NL: Issues in xenotransplantation. Liver Transpl Surg 1;320-321, 1995 https://doi.org/10.1002/lt.500010508
  16. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20;143-148, 2002 https://doi.org/10.1038/nbt0102-4
  17. Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia SJ: A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 125;173-181, 2005 https://doi.org/10.1016/j.jss.2004.11.036
  18. Rainaldi G, Calcabrini A, Santini MT: Positively charged polymer polylysine-induced cell adhesion molecule redistribution in K562 cells. J Mater Sci Mater Med 9;755-760, 1998 https://doi.org/10.1023/A:1008915305681
  19. Schultze JL, Grabbe S, von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 25;659-664, 2004 https://doi.org/10.1016/j.it.2004.09.016